Abstract 237P
Background
The purpose of this paper is to report the dosimetric effects of conscious sparing of contralateral lobe of thyroid gland in select head and neck patients receiving intensity-modulated radiotherapy to ipsilateral neck only. In unilaterally treated neck, the thyroid lobe present contralaterally is passively spared. We compared the effects of consciously sparing it and associated dosimetric results and their statistical significance.
Methods
Treatment plans of 38 buccal mucosa cancer patients, treated to ipsilateral side only, receiving same dose and fractionation to buccal mucosa & elective neck irradiation were evaluated. Since October 2021 we adopted a department protocol of conscious sparing of contralateral thyroid in unilaterally treated head and neck cancer patients. 19 of these had conscious sparing of contralateral thyroid (group A) whereas 19 of old plans were evaluated when C/L thyroid were not given constraints & are being passively spared due to location on contralateral/non treatment side of neck (group B). Treatment planning was done using 7 beam (6 MV) IMRT in Eclipse 13.7 TPS in all of these patients. The best treatment plans were selected ensuring 95% PTV dose coverage and acceptable dose to organs at risk (OARs). Uniform contouring, plan optimization and evaluation protocols were followed for all of these patients.
Results
The mean dose of thyroid in group A was 10.23Gy whereas in group B it was 19.35Gy which is statistically significant (P value – 0.0001). The mean thyroid volume in group A was 4.76cc and in group B was 5.86cc which is not significant statistically different from group B, thyroid dose. Table: 237P
Groups | No. | Mean ± SD | ‘t’ value | P value |
Thyroid dose with constraint | 19 | 10.23 ± 2.18 | 9.004, df=36 | 0.0001* |
Thyroid dose without constraint | 19 | 19.35 ± 3.84 |
Unpaired ‘t’ test applied. P value = 0.0001, Significant
Conclusions
Unilateral treatment of neck passively reduces dose to OARs present on the contralateral side. This study emphasizes that conscious sparing of contralateral thyroid lobe can further reduce the dose to significant levels. This reduction can preserve thyroid function further. Larger clinical trials are required to corroborate this dosimetric gain with clinical thyroid function preservation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
167P - Genetic testing for prostate cancer: The Indian scenario
Presenter: Ganesh Bakshi
Session: Poster viewing 03
168P - Transcriptional profiling of metastatic hormone sensitive prostate cancer (mHSPC) and distinct features are associated with clinical outcome
Presenter: BYULA JEE
Session: Poster viewing 03
169P - Urine tumor DNA fragmentation profiles provided a novel biomarker for early detection of prostate cancer
Presenter: Nianzeng Xing
Session: Poster viewing 03
170P - Safety, efficacy and pharmacoeconomic implications of low dose abiraterone in prostate cancer
Presenter: Suryakanta Acharya
Session: Poster viewing 03
171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
Presenter: Jin Cho
Session: Poster viewing 03
172P - Impact on management of non-metastatic prostate cancer biochemical recurrence with use of 68Ga PET-PSMA PET/CT scans in single-institution experience
Presenter: Pimchanok Tuitemwong
Session: Poster viewing 03
173P - Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Francis Parnis
Session: Poster viewing 03
175TiP - A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation
Presenter: Junlong Zhuang
Session: Poster viewing 03